Biohit Oyj - Managers' Transactions, March 1, 2017 at 11:50 am local time (EET)
| Person subject to the notification requirement | ||
| Name: | Euroclone Spa | Legal Person |
| Position: | Closely associated person | |
| Person discharging managerial responsibilities in issuer | ||
| Name: | Aiolfi, Franco | |
| Position: | Member of the Board/Deputy member | |
| Initial Notification | ||
| Reference number: | 74370089ATTSNBXJVT29_20170227134828_12 | |
| Issuer | ||
| Name: | Biohit Oyj | |
| LEI: | 74370089ATTSNBXJVT29 | |
| Transaction details | ||
| Transaction date: | 2017-02-24 | |
| Venue: | NASDAQ HELSINKI LTD (XHEL) | |
| Nature of the transaction: | Exercise (Rights, Put and Call Options) | |
| Instrument: | Share | |
| ISIN: | FI0009005482 | |
| Volume: | 475 | |
| Unit price: | 5,56000 Euro | |
| Volume: | 458 | |
| Unit price: | 5,57000 Euro | |
| Volume: | 1000 | |
| Unit price: | 5,56000 Euro | |
| Volume: | 200 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 200 | |
| Unit price: | 5,56000 Euro | |
| Volume: | 100 | |
| Unit price: | 5,57000 Euro | |
| Volume: | 1500 | |
| Unit price: | 5,57000 Euro | |
| Volume: | 200 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 150 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 62 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 200 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 69 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 35 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 50 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 200 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 1000 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 160 | |
| Unit price: | 5,55000 Euro | |
| Volume: | 25 | |
| Unit price: | 5,55000 Euro | |
| Aggregated transactions | ||
| Volume: | 6084 | |
| Volume weighted average price: | 5.55952 Euro | |
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com